Developer docs
API playgroundTry for free, no card

Search company profiles

Marcan Pharmaceuticals

Full company profile

uuid0009cp3

Namestring
Marcan Pharmaceuticals
Legal namestring
Marcan Pharmaceuticals Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Marcan Pharmaceuticals Inc. is a privately held Canadian generic pharmaceutical company headquartered in Ottawa, Ontario, and a wholly-owned subsidiary of Emcure Pharmaceuticals Ltd. since 2015. The company develops, markets, and distributes a portfolio of 170+ generic medications spanning oral solids and injectable formulations, with therapeutic coverage including oncology, cardiology, neurology, anti-infectives, psychiatry, endocrinology, and immunology. Vertical integration with parent Emcure provides access to 89 Active Pharmaceutical Ingredients and manufacturing capacity, while Marcan itself operates the Canadian regulatory, sales, and distribution layer with Health Canada Drug Identification Numbers on each product. Following the July 2026 CAD $50 million full acquisition of Mantra Pharma Inc., Marcan also owns the Quebec-based prescription drug and natural health product distribution subsidiary.

The company operates a B2B enterprise go-to-market with a dedicated Hospital & Institutional business unit supplying 150+ SKUs to 1,200+ hospitals across Canada, plus broader distribution reaching 1,000+ retail pharmacies and 700+ hospital pharmacies. Regional sales coverage spans Ontario, Western Canada, and Quebec through Account Managers reporting to a Senior Director National Sales, with regulatory affairs specialists supporting provincial formulary inclusion and Health Canada compliance. Patient support programs tied to specialty products (MAR-Fingolimod, MAR-Dimethyl Fumarate, MAR-Teriflunomide) provide reimbursement and co-pay assistance.

Revenue is generated through pharmaceutical product sales at regulated Canadian prices negotiated via provincial formularies and the pan-Canadian Pharmaceutical Alliance (pCPA). The portfolio is sold primarily through one-time B2B purchase transactions with pharmacy and institutional buyers rather than subscription or licensing models. With a 50+ employee workforce (more than double the prior 20-person base) and a sustained product launch cadence across multiple therapeutic categories, Marcan is in active scaling mode, though the February 2026 MAR-Amlodipine recall highlights quality-control risks inherent in generic manufacturing.

Short descriptiontext

Marcan Pharmaceuticals is an Ottawa-based generic drug distributor and subsidiary of India's Emcure Pharmaceuticals, marketing 170+ medications across oncology, neurology, cardiology, and anti-infectives to 1,200+ Canadian hospitals and 1,000+ retail pharmacies, now including Quebec subsidiary Mantra Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOttawa, Canada
HQ citystring
Ottawa
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals distribution, hospital pharmaceutical supply, branded generic medications, injectable pharmaceutical products, retail pharmacy distribution
Industry2 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Generic Pharmaceutical Sales
TypeOne Time License
Description

Manufacturing and distribution of branded and generic pharmaceutical products for the Canadian market. Products sold to retail pharmacies, hospital pharmacies, and healthcare institutions through B2B sales relationships.

marcanpharma.com
2Prescription Drug Distribution
TypeOne Time License
Description

Marketing and distribution of prescription drugs and natural health products through Mantra Pharma Inc. (Quebec-based subsidiary).

scanx.trade
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Others
Pricing details1 tier
1Account Manager - Ontario: $115,000-$130,000 salary range
ModelOtherBilling cadencePay-as-you-go
Notes

B2B pharmaceutical sales compensation includes base salary plus commissions based on territory performance. Healthcare professional and patient support programs available.

marcanpharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Mantra Pharma Inc.
Description

Subsidiary engaged in marketing and distribution of prescription drugs and natural health products in Canada, incorporated in Quebec.

business-standard.com
Core offering1 text field

Marcan Pharmaceuticals Inc. develops, manufactures, and distributes a portfolio of 170+ generic and branded-generic pharmaceutical products for the Canadian market, including oral and injectable dosage forms. The company operates two primary business lines — a Hospital & Institutional unit supplying over 150 SKUs to more than 1,200 hospitals, and a Retail Pharmacy distribution channel reaching over 1,000 retail pharmacies — leveraging vertically integrated manufacturing through its parent Emcure Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Fourfold growth compared to the Canadian market benchmark
+1 more record
Product overview1 text field

Marcan Pharmaceuticals Inc. is an Ottawa-based pharmaceutical company that develops, manufactures, and distributes generic pharmaceutical products for the Canadian market. The company operates as a subsidiary of Emcure Pharmaceuticals Ltd. following acquisition in 2015. Marcan's product portfolio consists of 170+ generic medications covering diverse therapeutic categories including antianginals, antidepressants, anticonvulsants, antibiotics, antineoplastics, antihistamines, and more. Products are available in multiple dosage forms including oral tablets, capsules, and injectable formulations. The company serves both retail and hospital pharmacies (over 1,100 retail and 700+ hospital pharmacies), and offers patient support programs for specialty medications like MAR-Fingolimod, MAR-Dimethyl Fumarate, and MAR-Teriflunomide. The portfolio includes branded generics (prefixed with 'MAR-') and pure generic formulations, with the Hospital & Institutional business unit providing over 150 SKUs to over 1,200 hospitals in Canada.

Product and service31 records
1MAR-Ranolazine XR
CategoryGeneric Pharmaceutical Product
Description

Extended-release antianginal tablets (500 mg) used to treat chronic angina. Distributed to Canadian retail and hospital pharmacies.

2Treosulfan for Injection
CategoryGeneric Pharmaceutical Product
Description

Antineoplastic alkylating agent injectable (5 g/vial) used in conditioning treatment prior to hematopoietic stem cell transplantation.

3MAR-ZOLMITRIPTAN
CategoryGeneric Pharmaceutical Product
Description

5-HT1 receptor agonist tablets (2.5 mg) used for acute migraine treatment.

4MAR-DOXEPIN
CategoryGeneric Pharmaceutical Product
Description

Tricyclic antidepressant/anxiolytic capsules (10–100 mg) for depression and anxiety disorders.

5MAR-DIENOGEST
CategoryGeneric Pharmaceutical Product
Description

Progestin tablets (2 mg) used for the treatment of endometriosis.

6Arsenic Trioxide for Injection
CategoryGeneric Pharmaceutical Product
Description

Antineoplastic injectable (10 mL vial) used in the treatment of acute promyelocytic leukemia.

7MAR-FLUOXETINE
CategoryGeneric Pharmaceutical Product
Description

SSRI antidepressant capsules (10 mg, 20 mg) for depression, OCD, and bulimia.

8MAR-AFATINIB
CategoryGeneric Pharmaceutical Product
Description

Protein kinase inhibitor tablets (20–40 mg) for non-small cell lung cancer treatment.

9MAR-LEFLUNOMIDE
CategoryGeneric Pharmaceutical Product
Description

Antirheumatic/immunomodulator tablets (10 mg, 20 mg) for rheumatoid arthritis.

10MAR-BILASTINE
CategoryGeneric Pharmaceutical Product
Description

Second-generation antihistamine tablets (20 mg) for allergic rhinitis and urticaria.

11MAR-METFORMIN XR
CategoryGeneric Pharmaceutical Product
Description

Extended-release oral antihyperglycemic tablets (500 mg, 1000 mg) for type 2 diabetes management.

12MAR-ESZOPICLONE
CategoryGeneric Pharmaceutical Product
Description

Non-benzodiazepine hypnotic tablets (1–3 mg) for the treatment of insomnia.

13Vancomycin Hydrochloride for Injection USP
CategoryGeneric Pharmaceutical Product
Description

Antibiotic injection (500 mg, 1 g, 5 g vials) for treatment of serious gram-positive bacterial infections.

14MAR-ETHOSUXIMIDE
CategoryGeneric Pharmaceutical Product
Description

Anticonvulsant capsules (250 mg) used in the treatment of absence seizures.

15Colistimethate for Injection USP
CategoryGeneric Pharmaceutical Product
Description

Polymyxin antibiotic injection (150 mg/vial) for treatment of multi-drug resistant gram-negative bacterial infections.

16BiCNU Carmustine for Injection
CategoryGeneric Pharmaceutical Product
Description

Antineoplastic sterile powder for reconstitution (100 mg) used in chemotherapy treatment regimens.

17acetaZOLAMIDE for Injection USP
CategoryGeneric Pharmaceutical Product
Description

Carbonic anhydrase inhibitor diuretic sterile powder for injection (500 mg/vial) for IV use.

18MAR-METFORMIN
CategoryGeneric Pharmaceutical Product
Description

Immediate-release oral antihyperglycemic tablets (500 mg, 850 mg) for type 2 diabetes management.

19MILRINONE LACTATE INJECTION USP
CategoryGeneric Pharmaceutical Product
Description

Inotropic/vasodilator injection (10 mg/10 mL) for short-term treatment of acute decompensated heart failure.

20MAR-CYPROHEPTADINE
CategoryGeneric Pharmaceutical Product
Description

First-generation antihistamine tablets (4 mg) used for allergy relief and appetite stimulation.

21PROPOFOL INJECTION
CategoryGeneric Pharmaceutical Product
Description

General anesthetic injectable emulsion (200–1000 mg vials) for induction and maintenance of anesthesia.

22MAR-APIXABAN
CategoryGeneric Pharmaceutical Product
Description

Direct oral anticoagulant tablets (2.5 mg, 5 mg) for prevention of stroke and blood clots.

23MAR-CLONIDINE
CategoryGeneric Pharmaceutical Product
Description

Alpha-2 agonist tablets (0.025 mg) for management of menopausal vasomotor symptoms.

24MAR-ONDANSETRON ODT
CategoryGeneric Pharmaceutical Product
Description

5-HT3 receptor antagonist orally disintegrating tablets (4 mg, 8 mg) for prevention of nausea and vomiting.

25MAR-MYCOPHENOLATE MOFETIL
CategoryGeneric Pharmaceutical Product
Description

Immunosuppressive oral suspension (200 mg/mL) used to prevent organ transplant rejection.

26ONDANSETRON INJECTION USP
CategoryGeneric Pharmaceutical Product
Description

Antiemetic sterile solution for IV injection (40 mg/20 mL) for prevention of chemotherapy-induced nausea.

27MAR-DIMETHYL FUMARATE
CategoryGeneric Pharmaceutical Product
Description

Immunomodulating delayed-release capsules (120 mg, 240 mg) for multiple sclerosis treatment.

28PENTAMIDINE ISETIONATE FOR INJECTION BP
CategoryGeneric Pharmaceutical Product
Description

Antimicrobial injection (300 mg/vial) for treatment and prevention of Pneumocystis pneumonia.

29MAR-Amlodipine
CategoryGeneric Pharmaceutical Product
Description

Calcium channel blocker antihypertensive tablets (2.5–10 mg) for hypertension and angina management.

30MAR-Fingolimod
CategoryGeneric Pharmaceutical Product
Description

S1P receptor modulator capsules (0.5 mg) for relapsing-remitting multiple sclerosis, with patient support program.

31MAR-Teriflunomide
CategoryGeneric Pharmaceutical Product
Description

Immunomodulator for multiple sclerosis management with risk management plan and patient educational materials.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-07-02
Description

Marcan Pharmaceuticals acquired 100% of Class E Special Shares in Mantra Pharma Inc. for CAD $50 million. Transaction completed July 2, 2026, consolidating full ownership of Mantra under Marcan. Mantra Pharma, incorporated in Quebec, Canada, is engaged in marketing and distribution of prescription drugs and natural health products with reported turnover of CAD 96.67 million in FY2026.

Strategic tierCoreTypeOthersAnnounced on2015-01-01
Description

Marcan was acquired by Emcure Pharmaceuticals Ltd. in 2015. Emcure is a vertically integrated global manufacturer and R&D leader. Through this partnership, Marcan continues to focus on development and growth of its Canadian portfolio with access to manufacturing capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Canadian specialty pharmaceutical company with strong focus on sterile injectable products for hospital and institutional markets. Comparable in the injectable niche that Marcan has been growing with 85+ injectable SKUs.

TypeDirect peer
Description

Canada's largest generic pharmaceutical manufacturer, headquartered in Toronto. Directly comparable as a generic pharma developer and distributor serving Canadian retail pharmacies, hospital formularies, and global markets with overlapping therapeutic categories.

TypeBroad incumbent
Description

Global generic pharmaceutical leader with substantial Canadian operations. Competes with Marcan across overlapping generic molecules sold to Canadian retail pharmacies and hospitals, but operates at much larger scale and broader international footprint.

TypeBroad incumbent
Description

Global generic and specialty pharmaceutical manufacturer with Canadian operations, particularly strong in injectables. Competes with Marcan across hospital injectable and oral generic categories in the Canadian market.

TypeDirect peer
Description

Privately held Canadian generic pharmaceutical company based in Montreal, Quebec. Direct peer serving similar retail pharmacy and hospital channels across Canada with comparable branded generic (pms-) portfolios and therapeutic coverage.

TypeBroad incumbent
Description

Sandoz is the world's largest generics company following its spin-off from Novartis and maintains a strong Canadian presence. Broad incumbent competing in the same hospital and retail generic channels that Marcan serves, across comparable therapeutic categories including injectables.

TypeDirect peer
Description

Canadian-owned generic pharmaceutical company focused on prescription generics, OTCs, and consumer health products. Direct competitor in the Canadian retail pharmacy and institutional channels across overlapping molecules.

TypeDirect peer
Description

Indian-headquartered generic pharmaceutical company with Canadian operations distributing branded and generic products to retail and hospital channels. Directly comparable vertically-integrated emerging-market manufacturer expanding in Canada.

TypeDirect peer
Description

Vertically integrated Indian generic manufacturer comparable to Marcan's parent Emcure. Uses a similar export-oriented model supplying finished dosages and APIs to regulated markets including North America, with overlapping molecule coverage in oncology, cardiovascular, and anti-infectives.

TypeDirect peer
Description

Canadian specialty generic pharmaceutical company headquartered in Mississauga, Ontario. Comparable as a mid-sized Canadian generic distributor serving hospital and retail markets with similar branded generic positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marcan Pharmaceuticals

Generic Pharmaceuticalsmarcanpharma.com

Marcan Pharmaceuticals is an Ottawa-based generic drug distributor and subsidiary of India's Emcure Pharmaceuticals, marketing 170+ medications across oncology, neurology, cardiology, and anti-infectives to 1,200+ Canadian hospitals and 1,000+ retail pharmacies, now including Quebec subsidiary Mantra Pharma.

What Marcan Pharmaceuticals does

Marcan Pharmaceuticals Inc. is a privately held Canadian generic pharmaceutical company headquartered in Ottawa, Ontario, and a wholly-owned subsidiary of Emcure Pharmaceuticals Ltd. since 2015. The company develops, markets, and distributes a portfolio of 170+ generic medications spanning oral solids and injectable formulations, with therapeutic coverage including oncology, cardiology, neurology, anti-infectives, psychiatry, endocrinology, and immunology. Vertical integration with parent Emcure provides access to 89 Active Pharmaceutical Ingredients and manufacturing capacity, while Marcan itself operates the Canadian regulatory, sales, and distribution layer with Health Canada Drug Identification Numbers on each product. Following the July 2026 CAD $50 million full acquisition of Mantra Pharma Inc., Marcan also owns the Quebec-based prescription drug and natural health product distribution subsidiary.

The company operates a B2B enterprise go-to-market with a dedicated Hospital & Institutional business unit supplying 150+ SKUs to 1,200+ hospitals across Canada, plus broader distribution reaching 1,000+ retail pharmacies and 700+ hospital pharmacies. Regional sales coverage spans Ontario, Western Canada, and Quebec through Account Managers reporting to a Senior Director National Sales, with regulatory affairs specialists supporting provincial formulary inclusion and Health Canada compliance. Patient support programs tied to specialty products (MAR-Fingolimod, MAR-Dimethyl Fumarate, MAR-Teriflunomide) provide reimbursement and co-pay assistance.

Revenue is generated through pharmaceutical product sales at regulated Canadian prices negotiated via provincial formularies and the pan-Canadian Pharmaceutical Alliance (pCPA). The portfolio is sold primarily through one-time B2B purchase transactions with pharmacy and institutional buyers rather than subscription or licensing models. With a 50+ employee workforce (more than double the prior 20-person base) and a sustained product launch cadence across multiple therapeutic categories, Marcan is in active scaling mode, though the February 2026 MAR-Amlodipine recall highlights quality-control risks inherent in generic manufacturing.

Marcan Pharmaceuticals firmographics

Firmographics
Name
Marcan Pharmaceuticals
Legal name
Marcan Pharmaceuticals Inc.
Website
https://marcanpharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Marcan Pharmaceuticals is an Ottawa-based generic drug distributor and subsidiary of India's Emcure Pharmaceuticals, marketing 170+ medications across oncology, neurology, cardiology, and anti-infectives to 1,200+ Canadian hospitals and 1,000+ retail pharmacies, now including Quebec subsidiary Mantra Pharma.
Ownership category
akta.pro rank

Marcan Pharmaceuticals industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Generic pharmaceuticals distribution
  • Hospital pharmaceutical supply
  • Branded generic medications
  • Injectable pharmaceutical products
  • Retail pharmacy distribution

Where Marcan Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Ottawa
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Marcan Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

  1. Generic Pharmaceutical Sales: Manufacturing and distribution of branded and generic pharmaceutical products for the Canadian market. Products sold to retail pharmacies, hospital pharmacies, and healthcare institutions through B2B sales relationships.
  2. Prescription Drug Distribution: Marketing and distribution of prescription drugs and natural health products through Mantra Pharma Inc. (Quebec-based subsidiary).

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goAccount Manager - Ontario: $115,000-$130,000 salary range

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Marcan Pharmaceuticals product offering

Product offering

Core offering

Marcan Pharmaceuticals Inc. develops, manufactures, and distributes a portfolio of 170+ generic and branded-generic pharmaceutical products for the Canadian market, including oral and injectable dosage forms. The company operates two primary business lines — a Hospital & Institutional unit supplying over 150 SKUs to more than 1,200 hospitals, and a Retail Pharmacy distribution channel reaching over 1,000 retail pharmacies — leveraging vertically integrated manufacturing through its parent Emcure Pharmaceuticals.

Product overview

Marcan Pharmaceuticals Inc. is an Ottawa-based pharmaceutical company that develops, manufactures, and distributes generic pharmaceutical products for the Canadian market. The company operates as a subsidiary of Emcure Pharmaceuticals Ltd. following acquisition in 2015. Marcan's product portfolio consists of 170+ generic medications covering diverse therapeutic categories including antianginals, antidepressants, anticonvulsants, antibiotics, antineoplastics, antihistamines, and more. Products are available in multiple dosage forms including oral tablets, capsules, and injectable formulations. The company serves both retail and hospital pharmacies (over 1,100 retail and 700+ hospital pharmacies), and offers patient support programs for specialty medications like MAR-Fingolimod, MAR-Dimethyl Fumarate, and MAR-Teriflunomide. The portfolio includes branded generics (prefixed with 'MAR-') and pure generic formulations, with the Hospital & Institutional business unit providing over 150 SKUs to over 1,200 hospitals in Canada.

Differentiator

Problem solved

Functional benefit

Brands

  • Mantra Pharma Inc. Subsidiary engaged in marketing and distribution of prescription drugs and natural health products in Canada, incorporated in Quebec.

Products and services

  • MAR-Ranolazine XR Extended-release antianginal tablets (500 mg) used to treat chronic angina. Distributed to Canadian retail and hospital pharmacies.
  • Treosulfan for Injection Antineoplastic alkylating agent injectable (5 g/vial) used in conditioning treatment prior to hematopoietic stem cell transplantation.
  • MAR-ZOLMITRIPTAN 5-HT1 receptor agonist tablets (2.5 mg) used for acute migraine treatment.
  • MAR-DOXEPIN Tricyclic antidepressant/anxiolytic capsules (10–100 mg) for depression and anxiety disorders.
  • MAR-DIENOGEST Progestin tablets (2 mg) used for the treatment of endometriosis.
  • Arsenic Trioxide for Injection Antineoplastic injectable (10 mL vial) used in the treatment of acute promyelocytic leukemia.
  • MAR-FLUOXETINE SSRI antidepressant capsules (10 mg, 20 mg) for depression, OCD, and bulimia.
  • MAR-AFATINIB Protein kinase inhibitor tablets (20–40 mg) for non-small cell lung cancer treatment.
  • MAR-LEFLUNOMIDE Antirheumatic/immunomodulator tablets (10 mg, 20 mg) for rheumatoid arthritis.
  • MAR-BILASTINE Second-generation antihistamine tablets (20 mg) for allergic rhinitis and urticaria.
  • MAR-METFORMIN XR Extended-release oral antihyperglycemic tablets (500 mg, 1000 mg) for type 2 diabetes management.
  • MAR-ESZOPICLONE Non-benzodiazepine hypnotic tablets (1–3 mg) for the treatment of insomnia.
  • Vancomycin Hydrochloride for Injection USP Antibiotic injection (500 mg, 1 g, 5 g vials) for treatment of serious gram-positive bacterial infections.
  • MAR-ETHOSUXIMIDE Anticonvulsant capsules (250 mg) used in the treatment of absence seizures.
  • Colistimethate for Injection USP Polymyxin antibiotic injection (150 mg/vial) for treatment of multi-drug resistant gram-negative bacterial infections.
  • BiCNU Carmustine for Injection Antineoplastic sterile powder for reconstitution (100 mg) used in chemotherapy treatment regimens.
  • acetaZOLAMIDE for Injection USP Carbonic anhydrase inhibitor diuretic sterile powder for injection (500 mg/vial) for IV use.
  • MAR-METFORMIN Immediate-release oral antihyperglycemic tablets (500 mg, 850 mg) for type 2 diabetes management.
  • MILRINONE LACTATE INJECTION USP Inotropic/vasodilator injection (10 mg/10 mL) for short-term treatment of acute decompensated heart failure.
  • MAR-CYPROHEPTADINE First-generation antihistamine tablets (4 mg) used for allergy relief and appetite stimulation.
  • PROPOFOL INJECTION General anesthetic injectable emulsion (200–1000 mg vials) for induction and maintenance of anesthesia.
  • MAR-APIXABAN Direct oral anticoagulant tablets (2.5 mg, 5 mg) for prevention of stroke and blood clots.
  • MAR-CLONIDINE Alpha-2 agonist tablets (0.025 mg) for management of menopausal vasomotor symptoms.
  • MAR-ONDANSETRON ODT 5-HT3 receptor antagonist orally disintegrating tablets (4 mg, 8 mg) for prevention of nausea and vomiting.
  • MAR-MYCOPHENOLATE MOFETIL Immunosuppressive oral suspension (200 mg/mL) used to prevent organ transplant rejection.
  • ONDANSETRON INJECTION USP Antiemetic sterile solution for IV injection (40 mg/20 mL) for prevention of chemotherapy-induced nausea.
  • MAR-DIMETHYL FUMARATE Immunomodulating delayed-release capsules (120 mg, 240 mg) for multiple sclerosis treatment.
  • PENTAMIDINE ISETIONATE FOR INJECTION BP Antimicrobial injection (300 mg/vial) for treatment and prevention of Pneumocystis pneumonia.
  • MAR-Amlodipine Calcium channel blocker antihypertensive tablets (2.5–10 mg) for hypertension and angina management.
  • MAR-Fingolimod S1P receptor modulator capsules (0.5 mg) for relapsing-remitting multiple sclerosis, with patient support program.
  • MAR-Teriflunomide Immunomodulator for multiple sclerosis management with risk management plan and patient educational materials.

Quantifiable outcome

  • Fourfold growth compared to the Canadian market benchmark
  • +1 more outcomes

Companies that use Marcan Pharmaceuticals

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Marcan Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Marcan Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Mantra Pharma Inc.coreStrategic or Co-development Partner · 2 July 2026Marcan Pharmaceuticals acquired 100% of Class E Special Shares in Mantra Pharma Inc. for CAD $50 million. Transaction completed July 2, 2026, consolidating full ownership of Mantra under Marcan. Mantra Pharma, incorporated in Quebec, Canada, is engaged in marketing and distribution of prescription drugs and natural health products with reported turnover of CAD 96.67 million in FY2026.
  • Emcure Pharmaceuticals Ltd.coreOthers · 1 January 2015Marcan was acquired by Emcure Pharmaceuticals Ltd. in 2015. Emcure is a vertically integrated global manufacturer and R&D leader. Through this partnership, Marcan continues to focus on development and growth of its Canadian portfolio with access to manufacturing capabilities.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Marcan Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • SteriMax Inc. Canadian specialty pharmaceutical company with strong focus on sterile injectable products for hospital and institutional markets. Comparable in the injectable niche that Marcan has been growing with 85+ injectable SKUs.

Direct peers

  • Apotex Inc. Canada's largest generic pharmaceutical manufacturer, headquartered in Toronto. Directly comparable as a generic pharma developer and distributor serving Canadian retail pharmacies, hospital formularies, and global markets with overlapping therapeutic categories.
  • Pharmascience Inc. Privately held Canadian generic pharmaceutical company based in Montreal, Quebec. Direct peer serving similar retail pharmacy and hospital channels across Canada with comparable branded generic (pms-) portfolios and therapeutic coverage.
  • JAMP Pharma Group: Canadian-owned generic pharmaceutical company focused on prescription generics, OTCs, and consumer health products. Direct competitor in the Canadian retail pharmacy and institutional channels across overlapping molecules.
  • Lupin Pharmaceuticals Canada: Indian-headquartered generic pharmaceutical company with Canadian operations distributing branded and generic products to retail and hospital channels. Directly comparable vertically-integrated emerging-market manufacturer expanding in Canada.
  • Aurobindo Pharma Ltd. Vertically integrated Indian generic manufacturer comparable to Marcan's parent Emcure. Uses a similar export-oriented model supplying finished dosages and APIs to regulated markets including North America, with overlapping molecule coverage in oncology, cardiovascular, and anti-infectives.
  • Mint Pharmaceuticals Inc. Canadian specialty generic pharmaceutical company headquartered in Mississauga, Ontario. Comparable as a mid-sized Canadian generic distributor serving hospital and retail markets with similar branded generic positioning.

Broad incumbents

  • Teva Pharmaceutical Industries Ltd. (Canada): Global generic pharmaceutical leader with substantial Canadian operations. Competes with Marcan across overlapping generic molecules sold to Canadian retail pharmacies and hospitals, but operates at much larger scale and broader international footprint.
  • Hikma Pharmaceuticals (Canada): Global generic and specialty pharmaceutical manufacturer with Canadian operations, particularly strong in injectables. Competes with Marcan across hospital injectable and oral generic categories in the Canadian market.
  • Sandoz (Novartis) Canada: Sandoz is the world's largest generics company following its spin-off from Novartis and maintains a strong Canadian presence. Broad incumbent competing in the same hospital and retail generic channels that Marcan serves, across comparable therapeutic categories including injectables.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Marcan Pharmaceuticals social profiles

Digital presence

Marcan Pharmaceuticals compliance and trust

Trust signal

Compliance4 records

Marcan Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marcan Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Marcan Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Marcan Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marcan Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marcan Pharmaceuticals

What does Marcan Pharmaceuticals do?

Marcan Pharmaceuticals Inc. develops, manufactures, and distributes a portfolio of 170+ generic and branded-generic pharmaceutical products for the Canadian market, including oral and injectable dosage forms. The company operates two primary business lines — a Hospital & Institutional unit supplying over 150 SKUs to more than 1,200 hospitals, and a Retail Pharmacy distribution channel reaching over 1,000 retail pharmacies — leveraging vertically integrated manufacturing through its parent Emcure Pharmaceuticals.

Is Marcan Pharmaceuticals a public or private company?

Marcan Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Marcan Pharmaceuticals founded?

Marcan Pharmaceuticals was founded in 2011. It employs 51 to 100 people.

Where is Marcan Pharmaceuticals based?

Marcan Pharmaceuticals is headquartered in Ottawa, Canada, in the North America region.

How does Marcan Pharmaceuticals make money?

Two revenue lines are on record. Generic Pharmaceutical Sales are the primary driver. The others are prescription Drug Distribution.

Who are Marcan Pharmaceuticals's main competitors?

SteriMax Inc. is listed as an emerging player. Direct peers are Apotex Inc., Pharmascience Inc., JAMP Pharma Group, Lupin Pharmaceuticals Canada, Aurobindo Pharma Ltd. and Mint Pharmaceuticals Inc.. Broad incumbents are Teva Pharmaceutical Industries Ltd. (Canada), Hikma Pharmaceuticals (Canada) and Sandoz (Novartis) Canada.

Does Marcan Pharmaceuticals have an API?

No public API is recorded for Marcan Pharmaceuticals.

What industry is Marcan Pharmaceuticals in?

Marcan Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business StandardMarcan Pharmaceuticals to invest CAD $50 million in Mantra Pharma Inc.Emcure Pharmaceuticals announced that its subsidiary Marcan Pharmaceuticals Inc. has acquired all Class E Special Shares in Mantra Pharma Inc. for an aggregate consideration of CAD $50 million. The transaction, completed on July 2, 2026, consolidates full ownership of Mantra under Marcan while maintaining the subsidiary structure within the Emcure group. Mantra Pharma Inc., incorporated in Quebec, Canada, is engaged in the marketing and distribution of prescription drugs and natural health products.CBCBlood pressure drug recalled after mix-up: Health CanadaA blood pressure medication has been recalled by Marcan Pharmaceuticals Inc. after a mix-up that may have led to some bottles containing the wrong drug. The recall involves two lots of MAR-Amlodipine, which could mistakenly contain midodrine, a drug used to treat low blood pressure.Daily Hive VancouverCanada issues urgent recall for blood pressure medicationHealth Canada issued an urgent recall notice for two lots of MAR-Amlodipine 5 mg tablets manufactured by Marcan Pharmaceuticals Inc., warning that some bottles may contain midodrine 2.5 mg tablets instead. The mix-up poses serious health risks including dangerously elevated blood pressure, dizziness, fainting, and organ damage, particularly for patients with conditions like pheochromocytoma, glaucoma, or hyperthyroidism. Health Canada is monitoring the company's investigation and has advised affected patients to return recalled bottles to their pharmacy for replacement and to seek medical attention if they experience symptoms like chest pain or sudden severe headache.NewswireTwo lots of MAR-Amlodipine 5 mg tablets recalled as some bottles may contain the wrong drugMarcan Pharmaceuticals Inc. is recalling two lots of MAR-Amlodipine 5 mg tablets (DIN 02371715, lots 2472021A with expiry July 2027) after discovering that some bottles may contain midodrine 2.5 mg tablets instead. The recall, issued by Health Canada on February 7, 2026, warns that substituting amlodipine (which treats high blood pressure) with midodrine (which treats low blood pressure) can cause dangerous blood pressure spikes, dizziness, fainting, and organ damage. Health Canada is monitoring the company's corrective and preventive actions and has advised patients to immediately return affected bottles to their pharmacy.Ottawa Business Journal‘Under the radar’ Ottawa firm Marcan Pharmaceuticals doubles office size and headcountMarcan Pharmaceuticals, an Ottawa-based generic drug manufacturer founded in 2005, has doubled its office space to nearly 11,000 square feet and expanded its workforce from 20 to over 50 employees to support four-times-faster growth than the Canadian market average. The company, acquired by India's Emcure Pharmaceuticals in 2015 and expanded through the 2023 acquisition of Quebec-based Mantra Pharma, now distributes products to over 12,000 Canadian pharmacies and is actively pursuing further acquisitions to scale operations.NewswireMarcan Pharmaceuticals becomes shareholder of Mantra PharmaMantra Pharma has entered into an agreement to bring Marcan Pharmaceuticals as a shareholder to support its growth objectives. The partnership aims to leverage Marcan's expertise and resources to expand Mantra's market presence in Quebec and across Canada, while also ensuring secure supply chains and product offerings.